SINOMAB BIO-B (03681): Wang Xiaosu has been appointed as a non-executive Director.

SINOMAB BIO-B (03681) issued an announcement that starting from December 19, 2024: (1) Shi Lei due to personal...

Zhitong FinanceDec 19 18:10

Express News | The USA Biological Security Act was not included in the CR bill.

BreakingsDec 18 15:53

The phase 1b clinical trial of China Antibody (03681.HK) SM17 has completed enrollment of all patients.

China Antibody (03681.HK) announced that on December 4, the Phase 1b clinical trial of SM17 (a humanized anti-IL-25 receptor monoclonal antibody for injection) for the treatment of moderate to severe atopic dermatitis has completed the enrollment of all 32 patients in China. This Phase 1b clinical trial started dosing the first patient on June 11, and the last patient's last site visit (LSLV) is expected to be completed by the end of March next year. The group expects to obtain topline data in the first quarter of next year. Previously, the company has completed the Phase 1 clinical trial of SM17 in both the usa and China.

AASTOCKSDec 9 17:31

The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!

Industry pessimistic expectations may improve.

Gelonghui FinanceDec 9 12:10

How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.

① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.

cls.cnDec 8 16:48

China Antibody-B (03681) and New Brightness-B (01952) have made progress in authorized cooperation, and the new BTK inhibitor SN1011 has achieved positive results in the phase 1b/2a clinical trial interim data.

This milestone result not only recognizes the huge potential of SN1011, but also marks an important milestone achievement in the authorized cooperation agreement between China Antibody and Yunding Xinyao.

Zhitong FinanceDec 4 16:00